Neuroscience

ACTRIMS

Florida

Poster

A phase 1, multicenter, single-arm, dose-escalation study of BMS-986353 (CC-97540), a CD19-directed chimeric antigen receptor T cell therapy manufactured using a next-generation process, evaluating safety and tolerability in patients with relapsing or progressive forms of multiple sclerosis (Breakfree-2)

Refik Pul, Bastian von Tresckow, Swathi Namburi, Claire Riley, Bonaventura Casanova, Ran Reshef, Francisco Pérez Miralles, Lisa Kelly, Rafael Sarmiento, Sharmila Das, Jerill Thorpe, Samantha By, Lingyun Lyu, Alexis Melton, Burhan Chaudhry, Ashley Koegel, Pavle Repovic.